Full-Time

Senior Quality Specialist

Updated on 8/1/2026

Bicara Therapeutics

Bicara Therapeutics

51-200 employees

Develops targeted therapies and tumor modulators

Compensation Overview

$105k - $128k/yr

Boston, MA, USA

Hybrid

Three days onsite per week required.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Visualization
GMP
Quality Assurance (QA)
Google Cloud Platform
Excel/Numbers/Sheets

Get referred to Bicara Therapeutics

See people who can refer or advise you

Requirements
  • A bachelor's degree in a scientific discipline or an equivalent combination of education and relevant industry experience.
  • A minimum of 5+ years of experience in Quality Assurance, Quality Systems, or Document Control within the biotechnology, pharmaceutical, or another regulated industry.
  • Experience working within GxP-regulated environments, including supporting GCP and/or GMP quality systems activities.
  • Working knowledge of document control processes and electronic Quality Management Systems.
  • Experience supporting quality systems activities such as audits, CAPAs, training management, controlled documentation, inspection readiness, and quality metrics reporting.
  • Strong proficiency in Microsoft Excel and experience using Smartsheet or similar electronic tracking and reporting tools.
  • Strong organizational, analytical, and problem-solving skills with the ability to manage multiple priorities and timelines in a fast-paced environment.
  • Strong attention to detail with the ability to work independently and collaboratively across functions.
  • Excellent written and verbal communication skills.
Responsibilities
  • Lead day-to-day document control activities within the electronic Quality Management System, including development, formatting, routing, review, approval, issuance, revision, archival, and retirement of controlled documents such as standard operating procedures, forms, templates, and logs in accordance with company procedures and applicable GxP requirements.
  • Organize, maintain, and archive GxP documentation outside the formal Quality Management System structure, ensuring that it is inspection-ready and easily retrievable.
  • Serve as an operational support resource for the GxP Quality Management System function, partnering with GMP Operations and Supplier Management and Clinical GCP Quality teams to support quality systems activities across the organization.
  • Develop and maintain training curricula and GxP tracking, and support deviation and corrective and preventive action processes, change control, management review, and inspection readiness.
  • Support internal and external audit scheduling and logistics, track audit status, and assist with follow-up activities to support the Director of GxP Auditing.
  • Develop and maintain quality metrics, dashboards, trackers, and trending tools, including Smartsheet and Microsoft Excel, to support quality assurance operational oversight, compliance monitoring, management review, and continuous improvement initiatives.
  • Collaborate cross-functionally with Quality and other internal and external departments to support quality systems improvements and compliance with applicable GxP requirements, including GCP and GMP activities.
  • Support additional Quality Systems initiatives and operational activities as assigned by the Senior Director of GxP Quality Management Systems.
Desired Qualifications
  • Experience in clinical-stage biotechnology or pharmaceutical environments.

Bicara Therapeutics develops cancer therapies that combine targeted precision treatment with tumor modulation. Their products deliver agents to cancer cells with high specificity while also adjusting the tumor environment to boost anti-cancer activity. This dual-action approach sets them apart from firms pursuing a single strategy, as they aim to both attack cancer cells and modify the tumor site through partnerships and regulatory navigation. The company’s goal is to improve patient outcomes by bringing effective, approvable therapies to market through research, trials, and eventual commercialization.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2020

Get referred to Bicara Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Phase 2/3 readout in HPV-negative recurrent/metastatic HNSCC creates a major catalyst.
  • $539.8 million cash extends runway into early 2029, reducing financing pressure.
  • Institutional conviction from Omega Fund Management supports partnering and follow-on funding.

What critics are saying

  • FORTIFI-HN01 failure would leave Bicara without approved products or revenue.
  • Single-asset dependence makes valuation highly sensitive to one clinical outcome.
  • Pembrolizumab controls the backbone regimen, raising efficacy hurdles for ficerafusp alfa.

What makes Bicara Therapeutics unique

  • First-in-class bifunctional EGFR/TGF-β antibody platform targets tumor cells and microenvironment.
  • Lead asset ficerafusp alfa is in Phase 2/3 for head and neck cancer.
  • Bicara is building a second program, BCA356, beyond the lead asset.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

1%